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Abstract
Background: Medication errors (ME) are an important problem in all hospitalized populations, especially in
intensive care unit (ICU). The aim of the study was to determine incidence, type and consequences of ME.
Materials and methods: Prospective observational cohort study during six weeks in a Moroccan ICU. Were
included all patients admitted for > 24 hours. ME were collected by two reviewers following three methods:
voluntary and verbally report by medical and paramedical staff, chart review and studying prescriptions and
transcriptions. Seriousness of events was classified from Category A: circumstances or events that have the capacity
to cause error, to Category I: patient’s death.
Results: 63 patients were eligible with a total of 509 patient-days, and 4942 prescription. We found 492 ME, which
incidence was 10 per 100 orders and 967 per 1000 patient-days. There were 113 potential Adverse Drug Events
(ADEs) [2.28 per 100 orders and 222 per 1000 patient-days] and 8 ADEs [0.16 per 100 orders and 15.7 per 1000
patient-days]. MEs occurred in transcribing stage in 60%cases. Antibiotics were the drug category in 33%. Two
ADEs conducted to death.
Conclusion: MEs are common in Moroccan medical ICU. These results suggest future targets of prevention
strategies to reduce the rate of ME.
Keywords: Medication Error, Intensive care unit, Adverse drug event, potential adverse drug event
Background
Iatrogenic injuries occur commonly in the health care
system. In recent years, medication error events received
considerable attention because of its substantial mortal-
ity, morbidity, and additional health care costs. Many
reports indicated that nearly one third of adverse drug
events (ADEs) are associated with medication errors and
are thus preventable [1-6]. The frequency of these events
was described over several studies. According to Brennan
et al [7] 3.7% of hospitalized patients experienced an
adverse event related to medical therapy in 1984. Of
these iatrogenic injuries, 69% were preventable. Later,
Lazarou et al [8] estimated that over 100.000 hospitalized
patients in 1994 had fatal adverse drug reactions. Bates et
al [9] reported 5 medication errors per 100 medication
orders; only 7 in 100 medication errors had significant
potential for harm. Other studies largely confirmed that
ADEs are common; and have important economic and
human consequences [3,10] as patients suffering from
ADEs have about three times the mortality rate com-
pared with matched controls, with an increase of about
two days in length of stay, and an increased cost of more
than $US2000 of admission. Thus, identification of ADEs
and medication errors appears to be a crucial first step in
improving patient safety, although the approach seems to
be different in research and routine care [11].
Estimates of ADEs rates vary substantially depending on
the setting and the data sources used. Intensive care units
(ICUs) can be considered as an optimal location for devel-
oping voluntary reporting incentives based on the fre-
quency of events. In fact, ICU patients may be at higher
risk for ADEs [12] because of the higher exposure to med-
icines and the weaker health conditions compared with
other patients. Cullen et al [13] reported twice combined
incidence of preventable and potential ADEs that rate in
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ordering and processing system may reduce the risk of
errors. Studies have demonstrated that some of these
interventions can be effective such us physician computer
order entry and a computerized clinical decision support
program [14-20].
In medical community, few epidemiological data are
available regarding the incidence, type and causes of medi-
c a t i o ne r r o r si nI C U s .L e s si n formation is available con-
cerning medication errors and ADEs in developing
countries and in Morocco. In this field, a pilot project
built by the World Alliance for Patient Safety in collabora-
tion with the World Health Organization program for
International Drug Monitoring was initiated in 2007. The
Moroccan Pharmacovigilance Centre was assigned as pro-
ject coordinator. As part of this project, a prospective
study in Moroccan medical ICU was initiated showing
7.7% medication errors for 1000 patient-days [12].
The aim of the present study was to evaluate inci-
dence, type and consequences of medication errors in a
Moroccan medical ICU.
Methods
Study design and setting
It was a prospective observational study conducted in a 12
bed medical ICU of Rabat University Hospital during six
weeks of September 2009. Rabat University Hospital is a
major teaching medical centre and the biggest hospital in
North Africa. It is referral for habitants in Western-North
Morocco.
The 12 bed medical ICU admits approximately 550
adult patients annually in order to treat medical urgent
diseases such us sepsis, metabolic and neurological ill-
ness. Elsewhere, surgical illness, complications after sur-
geries, neonates and burn patients are treated in
specialized units in Rabat University Hospital.
Before initiating this study, we gained the support of the
leader ship of nursing, pharmacy, medical staff, and admin-
istration who received informal seminars that emphasized
the roles of complex systems and human factors in predis-
posing to error, as opposed to individual blame. We
stressed the importance of understanding the epidemiology
and causes of error, and reinforced the multidisciplinary
nature of systems improvement. The study was conducted
after approving all aims, conditions and methods by the
local ethic committee named: the “comité d’éthique de la
recherche biomédicale“ of Rabat faculty of medicine and
pharmacy. Informed consent was obtained from all con-
scious patients and from families of comatose patients.
Patients
The study included consecutive patients hospitalized in
medical ICU during the study period at any degree of
disease severity, independently of their age and gender.
Patients excluded from the study were those transferred
to other units or died in medical ICU before registering
any medication error.
The following data were recorded for all patients using
the patient’s medical chart review: patient characteristics
(age and gender), Acute Physiology and Chronic Health
Evaluation II (APACHE II) score [21], diagnoses, dura-
tion of hospitalization, and outcome. Patients’ related
data was confidential, and was destroyed after collecting
information and constituting data base.
Inpatient Medication Use Process
A tt h et i m eo ft h es t u d y ,m e dication orders were hand-
written by physicians with guidelines for prescribers.
Medication supply to the patients was done by the nur-
sing staff from stock bottles of commonly used medicines
in the ward. The medicine stock bottles were held in a
central locked area. It was the chief of the nursing stuff
who is in charge of the stock ward. In accordance with
hospital policy, patients were also encouraged to bring
their own current medications into hospital. When a
charted medication was not held on the ward or available
as the patient’s own supply, the item was dispensed from
the hospital pharmacy.
For each administration, the date and the time of
medication administration were recorded on the admin-
istration section of the medication chart.
Identification of Medication-Related Events
One physician (N.J) trained all data collectors, who were
nurses, pharmacist, and physicians, in an identical man-
ner. During training, the unique perspectives of these dif-
ferent disciplines were shared to maximize appreciation
of potential error types and to develop a comprehensive,
uniform approach to error detection. Data collectors
worked 5 days per week, with recording of weekend data
on Mondays for patients still hospitalized. Two methods
of data collection were combined: observational study in
which investigators participated in daily physician rounds
and monitored ordering and transcribing medication.
Solicited reports from health professionals were the sec-
ond method of incident identification.
Data collectors identified medication errors, potential
ADEs and ADEs, by voluntary and verbally solicited
reports from house officers, nurses and pharmacists; and
by medication order sheet, medication administration
record, and chart review of all hospitalized patients on
study wards. On a given day, 1 data collector was assigned
to the study ward based on individual availability. Data
collected for each incident included name, dose, route and
category of drug, point in the system where the error
occurred, and type of error.
Reliable detection of medication errors requires coop-
eration and engagement of the staff, which depends in
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reporting.
Review Process
A physician (N.J) and a pharmacist (R.O) independently
reviewed suspected ADEs and potential ADEs and clas-
sified them as ADEs, potential ADEs, medication errors,
and rule violations. The physician reviewers rated ADEs
and potential ADEs according to the severity of injury
to the patient. The 2 evaluators resolved all disagree-
ments through discussion and consensus.
Definitions
T h ef o l l o w i n gd e f i n i t i o n sw e r et h o s ef r o mt h eN a t i o n a l
Coordinating Council for Medication Error Reporting
and Prevention [22]:
A medication error (ME) was defined as any error occur-
ring in the medication process (ordering, transcribing, dis-
pensing, administering, and monitoring). An example is an
order written for amoxicillin without a route of adminis-
tration. MEs are the broadest category and while most
have little potential for harm, some do and are either
potential ADEs or preventable ADEs depending on
whether an injury occurred.
Potential ADEs was defined as a medication error with
the potential to cause any injury but which does not actu-
ally cause any injury, either because of specific circum-
stances, chance or because the error was intercepted and
corrected (e.g. error was intercepted before the patient
was affected or the patient received a wrong dose but no
harm occurred) (Table 1). All potential ADEs are MEs
but not all MEs are potential ADEs.
ADEs were defined as any injury resulting from medical
interventions related to a drug. These events can be pre-
ventable (e.g. wrong dose) or non preventable (e.g. rash
due to an antibiotic). Non preventable ADEs are also
called adverse drug reactions (ADRs). The World Health
Organization (WHO) definition of ADRs excludes reac-
tions associated with error, which are of greatest interest
from the prevention perspective [11]. ADRs were not col-
lected in this study.
Seriousness of ADEs was classified on categories accord-
ing to WHO classification [23]: Category A: circumstances
or events that have the capacity to cause error. Category B:
an error occurred but the error did not reach the patient.
Category C: an error occurred that reached the patient but
did not cause patient harm. Category D: an error occurred
that reached the patient and required monitoring to con-
firm that it resulted in no harm to the patient and/or
required intervention to preclude harm. Category E:a n
error occurred that may have contributed to or resulted in
temporary harm to the patient and required intervention.
Category F: an error occurred that may have contributed
to or resulted in temporary harm to the patient a required
initial or prolonged hospitalization. Category G:a ne r r o r
occurred that may have contributed to or resulted in per-
manent patient harm. Category H: an error occurred that
required intervention necessary to sustain life. Category I:
an error occurred that may have contributed to or resulted
in the patient’s death.
Statistical analysis
Data are summarized as mean ± standard deviation for
variables with a normal distribution, median interquartile
range (IQR) for variables with skewed distributions, and
percentages for categorical variables. We reported rates of
errors per 100 orders, 100 admissions and 1000 patient-
day (Observation period of every patient included in the
study, from the admission in the ICU to leaving it, trans-
ferring in other service or dying). Statistical analyses were
carried out using SPSS version 13.0 (SPSS; Chicago, IL,
USA).
Results
Study Population
During the study period, a total of 63 eligible study
patients were admitted to the medical ICU. A total of 509
patient-days of admission, during which 4942 prescription
episodes were written.
The mean age of the study patients was 49 ± 21 years
and 37 (59%) were male. Mean APACHE II score was
11 ± 6. The median length of stay was 5 [4-10] days.
Table 1 Adverse drug events (ADEs) and potential ADEs: study definitions and examples [24]
Example Definitions Event type
Medication error (ME) Any injury in any stage of the medication process, including
ordering, transcribing, dispensing, administering or monitoring
A dose of non-critical medication is not given
Potential ADE An incident with potential for injury; all potential ADEs are ME An order was written for an overdose of medication
but the mistake was intercepted by the pharmacy
ADE Injury due to a drug Drug rush
Preventable Due to an error Coma due to over dose of sedative
Non preventable
(adverse drug
reaction)
Injury, but no error involved Allergic reaction in patient not known to be allergic
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rological disorders, 19 (30%) were respiratory disorders,
and 8 (13%) were hepatic and renal disorders (Table 2)
Identification of Medication-Related Events
A total of 4942 orders were reviewed, and prescription
rates were 7844 per 100 admission and 9709 prescrip-
tion per 1000 patient-days. We noted a total of 492
MEs. The incidence of MEs was 10 MEs per 100 orders,
780 MEs per 100 admissions, and 967 MEs per 1000
patient-days.
The frequency and rates of ADEs and potential ADEs
were 113 potential ADEs, and 8 ADEs. The 113 poten-
tial ADEs occurred at a rate of 2.28 per 100 orders,
179.3 per 100 admissions, and 222 potential ADEs per
1000 patient-days. There were 8 ADEs, which corre-
sponded to a rate of 0.16 ADEs per 100 prescription
episodes, 12.6 ADEs per 100 admissions, and 15.7 ADEs
per 1000 patient-days (Table 3).
ME characteristics and seriousness of events
From 492 MEs, 60% were noted at the stage of transcrip-
tion, and 35% at the stage of physician ordering. Con-
cerning the type of MEs, 73% of MEs were wrong route
of administration and 11% were wrong dose. Concerning
the drug category of MEs, 33% were antibiotics and 31%
were anticoagulants. From 113 potential ADEs, 60% were
noted at the stage of transcription, and 33% at the stage
of physician ordering. Concerning the type of potential
ADEs, 73% were wrong route of administration and 11%
were wrong dose. Concerning the drug category of
potential ADEs, 33% were antibiotics and 31% were
anticoagulants (Table 4).
Concerning the seriousness of events, Severity of ME
was in 75% assessed on category A, and in 22% assessed
on category B. Severity of potential ADEs was in 96%
assessed on category B. From 8 ADEs, 5 ADEs required
intervention necessary to sustain life (category H), and 2
ADEs were fatal (category I) (Table 5).
Discussion
I no u rs t u d y ,m e d i c a t i o ne r r o r sw e r ec o m m o ni nt h e
inpatient medical ICU setting. Potential ADEs occurred
more frequently than ADEs. The rate of medication
errors was high. Errors occurred most commonly at the
stage of drug ordering and transcribing. All types were
concerned but those essentially increased were drug
route and dosing errors. The drug classes associated
most frequently with errors were anti infective and
anticoagulants.
Comparing these results with those from a study by
Bates et al [9] using similar methods in an adult patient
population, our study had a higher rate of medication
errors (10 errors/100 orders in our study vs. 5.3/100
orders). In a clinical review [24], the rate of medical errors
among critically ill adults ranges from 1.2 to 947 errors
per 1000 patient-days with a median of 106 errors per
1000 patient-days, the incidence of medication errors in
our study seems then to be higher. However, a single cen-
tre study in a medical ICU [25] using an observation
method of medication administration reported a higher
rate with 1500 MEs per 1000 patient-days. In fact, a sys-
tematic review of ME incidence in different ICU types [26]
have found a wide variation in reported rates of MEs. We
believe thus, that much of this large variability was due to
differences in the definitions used of the same type of
event and also in methods used to detect events. Because
most MEs do not result in harm, it is logical that MEs are
more frequent than ADEs.
The incidence of ADEs and potential ADEs found in
our study is consistent with what is expected based upon
the literature. Several studies have focused on ME inci-
dence and few data are available concerning ADE and
portential ADE incidences [26]. To maximize the yield of
events, we used a multifaceted approach to event detec-
tion involving chart review supplemented by other meth-
ods, based on that undertaken by Cullen et al [13]. In our
study, the incidence of potential ADEs (222 per 1000
patient-days) was found to be about 20 times higher to
that reported by Cullen et al [13] (13.5 potential ADEs
per1000 patient-days). However, Rothschild et al [27] in a
cardiac surgery ICU using also a multifaceted approach
reported a rate of 23.8 potential ADEs per1000 patient-
days which is lower to ours. Measuring ADE rates is also
useful since this identifies actual situations in which
patients are harmed and also allows for change for safer
policies [26]. Concerning the incidence of ADEs, 15.7
ADEs per 1000 patient-days were noted in our study,
C u l l e ne ta l[ 1 3 ]i nam i x e dI CU using a multifaceted
Table 2 Epidemiological characteristics of the study
patients
Characteristics
Age (mean ± SD); years 49 ± 21
Gender n(%)
Male 37 (59)
Female 26 (41)
APACHE II (mean ± SD) 11 ± 6
Lengh of stay (median [IQR]); days 5 [4-10]
Diagnosis n(%)
Neurological disorders 21 (33)
Respiratory disorders 19 (30)
Hepatic and renal disorders 8 (13)
Infectious disorders 7 (11)
Intoxications 3 (5)
Others 5 (8)
APACHE II, Acute Physiology and Chronic Health Evaluation II score; IQR,
interquartile range.
Jennane et al. International Archives of Medicine 2011, 4:32
http://www.intarchmed.com/content/4/1/32
Page 4 of 7approach reported a rate of 5.1 ADEs per 1000 patient-
days. Rothschild et al [28] using the same method in a
mixed ICU reported much higher rate (37.6 ADEs per
1000 patient-days). The exact rate of events is difficult to
d e t e r m i n e ,b u ti th a sb e c o m ew i d e l ya c c e p t e dt h a tt h e
best estimate of the incidence of events requires compre-
hensive data collection using multiple strategies [26]. The
incidence of events is greatly influenced by the defini-
tions used, the method of detection and classification of
events, and the study setting [19]. This makes compari-
son of reported rates between studies extremely difficult
and, thus, any differences in rates should not be inter-
preted simply as reflecting differing levels of the quality
of care between institutions, but more as reflecting differ-
ences between study methodologies.
Previous studies have not reported criteria for defining
injury, and other studies have used multiple definitions
for the same type of event [26]. The reason for this
diversity of definitions is likely related to that fact that
no standard definition is accepted by all the major
organisations related to medication safety [26]. We used
a multidisciplinary approach that examined all aspects
of the medication system, from the physician’so r d e r
through administration of the drug to the patient. More-
over, we encouraged voluntary reporting by emphasizing
the role of systems problems in the origin of errors and
by nurturing a blame-free environment.
Although 35% of errors in our study occurred in drug
orders and 60% in drug transcribing many of these
errors were detected and corrected prior to the order
reaching the pharmacy. Cogent theories regarding the
origin of errors (often categorized as human factor
research) have been developed. Most investigators have
focused on problems in health care delivery systems that
predispose to error, rather than emphasizing the role of
individuals [29,30]. Ongoing multidisciplinary analysis of
incidents is important for developing further system
improvements
There were some limitations of the present study, our
study included only 63 admissions but 509 patient-days
of admission were noted and 4942 prescriptions episodes
were written which can be easily exploitable. The loca-
tion was a general hospital; there may be some limita-
tions to the generalizability of the results of the study to
other types of healthcare facilities. The scope of the study
was limited to MEs, ADEs and potential ADEs occurring
in hospitalized patients, and did not include outpatients.
It is however unlikely that any harmful events would
have been missed as such events would have prolonged
Table 3 Incidence of Medication Errors reported to prescriptions and admissions
Total N/100 orders N/100 admissions N/1000 patient-days
Orders 4942 NA* 7844 9709
Medication error 492 10 780 967
Adverse drug events 8 0.16 12.6 15.7
Potential adverse drug events 113 2.28 179.3 222
*NA indicates data not applicable.
Table 4 Characteristics of medication errors
Variables Medication errors Potential ADEs
n = 492 n = 113
Stage of errors, n(%)
Physician ordering 172 (35) 38 (33)
Transcribing 294 (60) 68 (60)
Administering 8 (2) 3 (3)
Dispensing 17 (3) 4 (4)
Error type, n(%)
Omission 15 (3) 4 (3)
Dose 57 (11) 12 (11)
Frequency 38 (8) 9 (8)
Route of administration 357 (73) 82 (73)
Patient monitoring 7 (1) 2 (2)
Missing 18 (4) 4 (3)
Drug category, n(%)
Anti-infective drugs 162 (33) 37 (33)
Anticoagulants 152 (31) 35 (31)
Corticoids 45 (9) 10 (9)
Analgesic and sedatives 20 (4) 5 (4)
Vasoactives drugs 25 (5) 4 (3)
Perfusion 6 (1) 2 (2)
Others 82 (17) 20 (18)
ADEs, Adverse Drug Events.
Table 5 Seriousness classification of medication errors
(MEs), adverse drug events (ADEs), and potential ADEs
Classification ME ADEs Potential ADEs
(n = 492) (n = 8) (n = 113)
Category A 371 0 0
Category B 109 0 109
Category C 20 2
Category D 20 2
Category E 00 0
Category F 00 0
Category G 11 0
Category H 55 0
Category I 22 0
Seriousness of ADEs was classified on categories according to WHO
classification [22].
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mission of the patient. However, our study has the
strength point to compare both the results of MEs and
ADEs with the literature data.
Our review of the literature highlighted 2 important
findings. First, medication error rates vary widely among
clinical settings (both ICU and non-ICU settings), patient
populations and studies. The reasons for this variation are
likely multifactorial, but the reasons may include different
patient populations (illness severity, number and type of
prescriptions) clinical practice variation, lack of uniformity
of definitions, the processes under investigation (e.g., pre-
scription, transcription), methods of reporting and the cul-
ture of the different centers reporting their data [31]. The
lack of standard definitions and reporting techniques
make comparisons across organizations, regions or coun-
tries difficult. Second, although there are many potential
risk factors for medication errors, the strongest evidence
that critically ill patients are at increased risk of a medica-
tion error are increased severity of illness; failure to docu-
ment the patient’s usual medication list; prescription of
cardiovascular, sedative, analgesic, anticoagulant or anti-
infective medications; prescription of each additional med-
ication; admission to a medical ICU compared with a
surgical ICU [31].
Potential strategies to prevent medication errors in the
ICU are focused on 7 prevention strategies: eliminating
extended physician work schedules, computerizing physi-
cian order entry, implementing support systems for clini-
cal decisions, computerizing intravenous devices, having
pharmacists participate in the ICU, reconciling medica-
tions and standardizing medications [31].
The practical approach is to recognize that errors are
a reality of medicine and that all health care providers
have a responsibility to ensure patient safety and to use
caution in promoting interventions. Improved medica-
tion safety may be accomplished by optimizing the
safety of the medication process, eliminating situational
risk factors and adopting strategies to intercept errors
and mitigate their consequences.
Conclusion
The medical use process itself is a complex system, pro-
viding many opportunities of ME occurring. Our inci-
dence of ME was generally similar to that of others ICU
studies which used similar methods of detection events.
All types and categories were identified with high preva-
lence of transcribing error and wrong route, drugs incrimi-
nated was antibiotics and anticoagulants. These results can
be used to improve quality of health care delivery; some
authors recommended focusing on computerized
approach like a first step to prevention in ICU in develop-
ing and developed countries. We believe that this
improvement research is an expensive technology in our
developed countries. We recommend standardization of
therapeutic protocols and a systematic checking of pre-
scriptions and transcriptions to reduce incidence of ME.
Key messages
Medication errors in a medical ICU
List of abbreviations
ADE: adverse drug event; ADR: adverse drug reaction; ICU: intensive care
unit; IQR: interquartile range; ME: Medication error; WHO: World Health
Organization.
Acknowledgements
We would like to thank the medical and paramedical stuff of medical ICU of
Ibn Sina University hospital for its nice cooperation in the study.
Author details
1Medical Intensive Care Unit, Ibn Sina University Hospital, Rabat, Morocco.
2Emergency Poison Unit, Hygiene Institute, Rabat, Morocco.
3Laboratory of
Biostatistics, Clinical and Epidemiological Research, Faculty of Medicine,
Rabat, Morocco.
Authors’ contributions
NJ drafted the manuscript, and participated in the acquisition of data. NM
drafted the manuscript, participated in the acquisition of data and the study
design. RO participated in the acquisition of data. KA helped to draft the
manuscript, and participated in the acquisition of data. IK helped to draft
the manuscript. JH participated in the coordination of the study. TD
participated in the coordination of the study. AAZ participated in the design
of the study, and performed the statistical analysis. RA conceived of the
study, participated in the design of the study, performed the statistical
analysis and interpretation of data, and gave the final approval of the
manuscript. All authors read and approved the final manuscript
Competing interests
The authors declare that they have no competing interests.
Received: 18 April 2011 Accepted: 4 October 2011
Published: 4 October 2011
References
1. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ,
Shea BF, Hallisey R: Incidence of adverse drug events and potential adverse
drug events: implications for prevention. JAMA 1995, 274:29-34.
2. Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, Gallivan T,
Hallisey R, Ives J, Laird N, Laffel G: Systems analysis of adverse drug
events. JAMA 1995, 274:35-43.
3. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, Small SD,
Sweitzer BJ, Leape LL: The costs of adverse drug events in hospitalized
patients. JAMA 1997, 227:307-311.
4. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP: Adverse drug events
in hospitalized patients: excess length of stay, extra costs, and
attributable mortality. JAMA 1997, 277:301-306.
5. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in
hospitalized patients: a meta analysis of prospective studies. JAMA 1998,
279:1200-1205.
6. Bates DW, Leape LL, Petrycki S: Incidence and preventability of adverse
drug events in hospitalized adults. J Gen Intern Med 1993, 8:289-294.
7. Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lawthers AG,
Newhouse JP, Weiler PC, Hiatt HH: Incidence of adverse events and
negligence in hospitalized patients: Results from the Harvard Medical
Practice Study I. N Engl J Med 1991, 324:370-376.
8. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in
hospitalized patients: a meta-analysis of prospective studies. JAMA 1998,
279:1200-1205.
9. Bates DW, Boyle DL, Vander Vliet MB, Schneider J, Leape LL: Relationship
between medication errors and adverse drug events. J Gen Intern Med
1995, 10:199-205.
Jennane et al. International Archives of Medicine 2011, 4:32
http://www.intarchmed.com/content/4/1/32
Page 6 of 710. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP: adverse drug events
in hospitalized patients. Excess length of stay, extra costs, and
attributable mortality. JAMA 1997, 277:301-306.
11. Gandhi TK, Seger DL, Bates DW: Identifying drug safety issues: from
research to practice. Int J Qual Health Care 2000, 12:69-76.
12. Benkirane RR, Abouqal R, Haimeur CC, Ech Cherif S, El Kettani SS,
Azzouzi AA, M’daghri Alaoui AA, Thimou AA, Nejmi MM, Maazouzi WW,
Madani NN, R-Edwards I, Soulaymani RR: Incidence of adverse drug events
and medication errors in intensive care units: a prospective multicenter
study. J Patient Saf 2009, 5:16-22.
13. Cullen DJ, Sweitzer BJ, Bates DW, Burdick E, Edmondson A, Leape LL:
Preventable adverse drug events in hospitalized patients: a comparative
study of intensive care and general care units. Crit Care Med 1997,
25:1289-1297.
14. Bates DW, Leape LL, Cullen DJ, Laird N, Petersen LA, Teich JM, Burdick E,
Hickey M, Kleefield S, Shea B, Vander Vliet M, Seger DL: Effect of
computerized physician order entry and a team intervention on
prevention of serious medication errors. JAMA 1998, 280:1311-1316.
15. Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI,
Bates DW: Pharmacist Participation on physician rounds and adverse
drug events in the intensive care unit. JAMA 1999, 282:267-270.
16. Evans RS, Pestotnik SL, Classen DC, Clemmer TP, Weaver LK, Orme JF Jr,
Lloyd JF, Burke JP: A computer-assisted management program for
antibiotics and other antiinfective agents. N Engl J Med 1998,
338:232-238.
17. Folli HL, Poole RL, Benitz WE, Russo JC: Medication error prevention by
pharmacists in two children’s hospitals. Pediatrics 1987, 79:718-722.
18. Barber N, Rawlins M, Dean Fanklin B: Reducing prescribing error:
Competence, control, and culture. Qual Saf Health Care 2003, 12:29-32.
19. Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW: Adverse drug
events and medication errors: detection and classification methods. Qual
Saf Health Care 2004, 13:306-314.
20. Takata GS, Mason W, Taketomo C, Logsdon T, Sharek PJ: Development,
testing and findings of pediatric focused trigger tool to identify
medication-related harm in US children’s hospitals. Pediatrics 2008,
121:927-935.
21. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II A severity of
disease classification system. Crit Care Med 1985, 13:818-829.
22. National Coordinating Council for Medication Error Reporting and
Prevention (NCC MERP): NCC MERP index for categorizing medication
errors.[http://www.Nccmerp.org], (accessed 20 January 2003).
23. WHO collaborating centre for International Drug Monitoring (UMC): Safety
Monitoring of Medicinal Products: Guidelines for Setting Up and Running a
Pharmacovigilance Centre London, UK: EQUUS; 2000.
24. Moyen E, Camiré E, Stelfox HT: Clinical review: Medication errors in critical
care. Crit Care 2008, 12:208.
25. Tissot E, Cornette C, Demoly P, Jacquet M, Barale F, Capellier G: Medication
errors at the administration stage in an intensive care unit. Intensive Care
Med 1999, 25:353-359.
26. Wilmer A, Louie K, Dodek P, Wong H, Ayas N: Incidence of medication
errors and adverse drug events in the ICU: a systematic review. Qual Saf
Health Care 2010, 19:e7.
27. Rothschild JM, Keohane CA, Cook EF, Orav EJ, Burdick E, Thompson S,
Hayes J, Bates DW: A controlled trial of smart infusion pumps to improve
medication safety in critically ill patients. Crit Care Med 2005, 33:533-540.
28. Rothschild JM, Landrigan CP, Cronin JW, Kaushal R, Lockley SW, Burdick E,
Stone PH, Lilly CM, Katz JT, Czeisler CA, Bates DW: The Critical Care Safety
Study: The incidence and nature of adverse events and serious medical
errors in intensive care. Crit Care Med 2005, 33:1694-1700.
29. Leape LL: Error in medicine. JAMA 1994, 272:1851-1857.
30. Glauber J, Goldmann DA, Homer CJ, Berwick DM: Reducing medical error
through systems improvement the management of febrile infants.
Pediatrics 2000, 105:1330-1332.
31. Camiré E, Moyen E, Stelfox HT: Medication errors in critical care: risk
factors, prevention and disclosure. CMAJ 2009, 180:936-943.
doi:10.1186/1755-7682-4-32
Cite this article as: Jennane et al.: Incidence of medication errors in a
Moroccan medical intensive care unit. International Archives of Medicine
2011 4:32.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Jennane et al. International Archives of Medicine 2011, 4:32
http://www.intarchmed.com/content/4/1/32
Page 7 of 7